Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Solid Tumours
Interventions: Selumetinib, Moxifloxacin, selumetinib placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Schizophrenia
Interventions: Aripiprazole IM Depot; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 96
States / cities: Chandler, Arizona • Anaheim, California • Cerritos, California + 78 more

Conditions: Antibiotic Resistance, Ocular Surface Microbiome, Gut Resistome
Interventions: Moxifloxacin (Topical); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteer
Interventions: ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinusitis, Sphenoidal, Chronic Sinusitis - Frontoethmoidal, Nasal Polyps, Nasal Polyp - Posterior
Interventions: gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic; Drug
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: varegacestat, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Parkinson's Disease, Off Episodes of Parkinson Disease
Interventions: APL-130277, Placebo, Moxifloxacin; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 10
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more

Conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions: Lumateperone 42 mg, Risperidone 2 mg; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: aripiprazole; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Erectile Dysfunction, Penile Prosthesis Infection
Interventions: Doxycycline, Ciprofloxacin, Augmentin, Bactrim; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 35 Years to 90 Years · Male only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: QTc Interval
Interventions: Droxidopa, Moxifloxacin, Placebo; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Schizophrenia
Interventions: Aripiprazole, placebo; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gonorrhea
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Keratoconus, Ectasia, Degeneration
Interventions: Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.); Drug
Lead sponsor: Cxlusa; Industry
Eligibility: 12 Years and older
Enrollment: 3,493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more

Conditions: Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions: Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 117,911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Urinary Tract Infection
Interventions: Fosfomycin tromethamine, Levofloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Sylmar, California • Torrance, California • Decatur, Georgia + 9 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 28
States / cities: Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more

Conditions: Cystic Fibrosis
Interventions: Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Autistic Disorder
Interventions: Aripiprazole, Placebo, D-cycloserine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Moxifloxacin, ALKS 5461, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Corneal Health, Cataract Surgery
Interventions: besivance, vigamox; Drug
Lead sponsor: Ophthalmology Consultants, Ltd.; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Bipolar Disorder, Mania
Interventions: aripiprazole (Abilify); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: aripiprazole (Abilify), ziprasidone (Geodon); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Antibiotic Resistance In Eye Surgeries

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis

A Cardiac Liability Study of Varegacestat in Healthy Participants

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

Collaborative Urological Prosthetics Investigation Directive Research Group

Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

Antimicrobial Susceptibility Patterns of N. Gonorrhea Isolates in an Era of Quinolone Resistance

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes